Abstract
Deep infiltrating endometriosis (DIE) is associated with chronic pelvic pain, dysmenorrhea, deep
dyspareunia, bowel and urinary symptoms, infertility, and impaired quality of life. Management includes
hormonal treatment and surgery, but the comparative benefits and risks of these approaches remain
uncertain. This review examines evidence concerning pain relief, quality of life, fertility, recurrence, and
treatment-related complications in women with DIE. The available literature includes a limited number of
direct comparisons between surgery and hormone-based treatment, together with observational surgical
cohorts and studies comparing different surgical techniques. Both medical and surgical treatment have been
associated with improvement in endometriosis-related pain. Surgical cohorts also report improvements in
quality of life and bowel function, and pregnancies have been documented after excision of deep disease.
However, most postoperative studies lack a nonsurgical control group, and comparisons between surgical
techniques do not establish the relative effectiveness of surgery and medical treatment. Recurrence and
clinically important bowel and urinary complications remain relevant considerations. The available evidence
does not establish that surgery is universally superior to medical treatment. Management should therefore
be individualized according to symptoms, lesion location and extent, reproductive plans, previous
treatment, and the risks associated with the proposed intervention. The certainty of comparative
Conclusions
is limited by the predominance of observational evidence and the inadequate recruitment of the
available randomized trial.
Categories:
Obstetrics/Gynecology
Keywords
deep infiltrating endometriosis, endometriosis surgery, fertility, hormonal treatment, surgical
complications
Introduction
And Background
Endometriosis is a chronic inflammatory disease characterized by the presence of endometrium-like tissue
outside the uterine cavity. It may cause dysmenorrhea, chronic pelvic pain, deep dyspareunia, bowel or
urinary symptoms, infertility, and reduced health-related quality of life. Deep infiltrating endometriosis
(DIE), also termed deep endometriosis, refers to disease that extends into deeper pelvic tissues and may
involve the uterosacral ligaments, rectovaginal septum, bowel, bladder, and ureters. The location and extent
of these lesions influence the symptoms, anatomical distortion, and complexity of treatment
[1-4]
.
Surgical treatment aims to remove endometriotic lesions and relieve associated fibrosis, adhesions, and
anatomical distortion. Depending on the location and extent of disease, procedures may include
laparoscopic excision, rectal shaving, discoid excision, segmental bowel resection, bladder excision, and
ureterolysis or reconstruction
[5]
. Extensive disease may require a multidisciplinary team involving
gynecologists, colorectal surgeons, urologists, radiologists, and fertility specialists. Although surgery may
improve pain and organ-related symptoms, it also carries risks of bowel, urinary tract, vascular,
neurological, and other complications. Persistent symptoms and recurrence may occur despite apparently
complete excision
[6]
.
Medical treatment principally aims to control symptoms by suppressing hormonal stimulation of
endometriotic tissue. Treatment options include combined hormonal contraceptives, progestogens,
levonorgestrel-releasing intrauterine systems, gonadotropin-releasing hormone (GnRH) agonists, and GnRH
antagonists. These treatments avoid the immediate risks of major surgery and may provide symptom
control, although adverse effects, incomplete symptom relief, and recurrence after discontinuation can limit
their effectiveness. Hormonal suppression also generally prevents attempts at spontaneous conception
while treatment continues
[7,8]
.
1
2
3
4
5
Open Access Review Article
How to cite this article
Jesmin M, Tasnim S, Begum M, et al. (November 18, 2026) Surgery Versus Medical Treatment for Deep Infiltrating Endometriosis: A Systematic
Review of Pain, Quality of Life, Fertility, Recurrence, and Treatment-Related Complications. Cureus 18(11): e119919.
DOI 10.7759/cureus.119919
The European Society of Human Reproduction and Embryology guideline recommends individualized
management, consideration of surgery for pain, and referral of women with deep disease to centers with
appropriate expertise
[9]
. However, these recommendations do not establish that surgery is more effective
than medical treatment for every patient.
Direct comparison of these approaches is challenging. Women selected for surgery may have more extensive
anatomical disease, severe symptoms, or inadequate responses to previous medical treatment. Conversely,
women receiving medical treatment may differ in their fertility intentions, comorbidities, surgical
suitability, and treatment preferences. The DIAMOND randomized controlled trial was designed to compare
laparoscopic surgery with optimized medical management for deep endometriosis, but inadequate
recruitment prevented a definitive comparison
[10]
.
Consequently, an important evidence gap remains regarding the comparative effectiveness and safety of
surgery and medical treatment. Postoperative improvements reported in surgical cohorts provide useful
clinical information but cannot independently establish superiority over medical management. This review
therefore examines direct comparative evidence alongside complementary primary studies reporting
outcomes after surgery for DIE. The objective is to assess evidence concerning pain relief, quality of life,
fertility, recurrence, and treatment-related complications while distinguishing postoperative improvement
from evidence of comparative treatment effectiveness.
Review
Materials and methods
Study Design and Reporting Framework
This systematic review was conducted and reported in accordance with the PRISMA 2020 statement
[11]
.
The literature-search methods were reported with reference to the PRISMA-S extension
[12]
. The review
question, eligibility criteria, information sources, data-extraction procedures, and evidence-synthesis
framework were established before final study selection. The review was not prospectively registered, and no
registration number was assigned. Formal risk-of-bias assessment was not performed.
Review Question and Eligibility Criteria
The review population comprised reproductive-age women diagnosed with DIE through surgery,
histopathology, or appropriate imaging. Eligible interventions included surgical excision and medical
treatment with hormonal therapies. The primary outcome was endometriosis-associated pain, including
chronic pelvic pain, dysmenorrhea, deep dyspareunia, and dyschezia. Secondary outcomes included
validated quality-of-life measures, spontaneous pregnancy, clinical pregnancy, live birth, recurrence, repeat
intervention, medication-related adverse effects, surgical complications, hospitalization, and cost-
effectiveness.
Eligible study designs included randomized controlled trials, prospective comparative studies, retrospective
comparative cohorts, and primary observational studies reporting relevant clinical outcomes after treatment
for DIE. Direct comparisons between surgery and medical treatment constituted the principal evidence
category. Surgical cohorts without a medical comparator were included as complementary evidence for
postoperative outcomes but were not considered direct comparisons of treatment effectiveness. Studies
comparing different surgical techniques, including rectal shaving and segmental resection, were analyzed
separately.
Studies involving superficial endometriosis or isolated ovarian endometriomas were excluded unless DIE-
specific outcomes could be extracted. Case reports, editorials, opinion articles, and studies without relevant
clinical outcomes were excluded from the primary evidence synthesis. Systematic reviews and clinical
guidelines were used for background information and citation searching but were not counted as primary
studies.
Information Sources and Search Strategy
A comprehensive literature search was conducted using five electronic databases: MEDLINE through
PubMed, Embase, Scopus, Web of Science Core Collection, and the Cochrane Central Register of Controlled
Trials (CENTRAL). The searches covered the period from database inception to August 31, 2026. Reference
lists of eligible primary studies and relevant systematic reviews were also examined to identify additional
potentially eligible publications.
The search strategy combined controlled vocabulary, where available, with free-text terms relating to DIE,
bowel endometriosis, rectovaginal endometriosis, surgery, excision, hormonal therapy, progestogens, and
GnRH agonists or antagonists. Outcome-related terms included pain, quality of life, pregnancy, live birth,
recurrence, and complications. No lower publication-date limit was applied.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
2
of
13
The following search strategy was used in PubMed: (("Endometriosis"[Mesh] OR
endometriosis[Title/Abstract] OR "deep endometriosis"[Title/Abstract] OR "deep infiltrating endometriosis"
[Title/Abstract] OR "bowel endometriosis"[Title/Abstract] OR "rectovaginal endometriosis"[Title/Abstract])
AND (surgery[Title/Abstract] OR surgical[Title/Abstract] OR excision[Title/Abstract] OR
laparoscopy[Title/Abstract] OR "rectal shaving"[Title/Abstract] OR "segmental resection"[Title/Abstract] OR
"medical treatment"[Title/Abstract] OR hormonal[Title/Abstract] OR progestogen[Title/Abstract] OR
progestin[Title/Abstract] OR "gonadotropin-releasing hormone"[Title/Abstract] OR GnRH[Title/Abstract]))
Equivalent search concepts were adapted for Embase, Scopus, Web of Science Core Collection, and
CENTRAL. The database-specific search strategies and dates of execution were documented. Records
retrieved from each database were recorded and incorporated into the study-selection process presented in
the PRISMA 2020 flow diagram.
Study Selection and Data Extraction
All records retrieved from the five databases and additional citation searching were consolidated in
reference-management software. Duplicate records were removed before screening. Two reviewers
independently screened titles and abstracts against the predefined eligibility criteria. Full texts of
potentially eligible publications were subsequently assessed independently by the same reviewers.
Disagreements regarding study eligibility were resolved through discussion and consensus. Reasons for
exclusion at the full-text stage were documented. Publications reporting results from the same patient
cohort were identified and linked to avoid double-counting participants.
Data were extracted from the included studies using a structured approach. Extracted variables included
author, publication year, country, study design, sample size, diagnostic criteria, lesion location, baseline
symptoms, previous treatment, surgical technique, medical regimen, and follow-up duration. Clinical
outcomes included pain scores, quality-of-life measures, spontaneous and clinical pregnancy, live birth,
recurrence, repeat intervention, and treatment-related complications. Adjusted estimates and CIs were
recorded when reported in the original publications.
Risk of Bias and Synthesis
Formal risk-of-bias assessments using the Cochrane Risk of Bias 2 (RoB 2) tool and the Risk Of Bias In Non-
randomized Studies of Interventions (ROBINS-I) tool were not performed
[13,14]
. Accordingly, no formal
study-level risk-of-bias judgments were assigned. Methodological limitations were considered descriptively,
with attention to potential confounding by indication, patient selection, intervention classification, missing
outcome data, outcome measurement, and selective reporting.
A narrative synthesis was undertaken because the included studies differed in design, disease location,
treatment regimen, surgical technique, and outcome definitions. Direct comparisons between surgery and
medical treatment were synthesized separately from uncontrolled surgical cohorts and studies comparing
different surgical techniques. Where available, original study-reported effect estimates, CIs, and p-values
were considered in interpreting individual findings. Meta-analysis was not performed because the available
evidence was insufficiently homogeneous to support valid pooling. No pooled treatment-effect estimate was
calculated.
Results
A total of 2,491 records were identified through electronic database searches and additional sources. After
removal of 519 duplicates, 1,972 records underwent title and abstract screening. Following screening and
full-text eligibility assessment, eight primary studies met the inclusion criteria and were included in the
qualitative synthesis. The identification, screening, eligibility assessment, and inclusion processes are
summarized in the PRISMA 2020 flow diagram (Figure
1
).
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
3
of
13
FIGURE
1: PRISMA 2020 flow diagram of study identification, screening,
eligibility assessment, and inclusion in the systematic review.
The flow diagram illustrates the study selection process for the systematic review. A total of 2,491 records were
identified through database searches (n = 2,417) and additional sources (n = 74). After removing 519 duplicates,
1,972 records underwent title and abstract screening, of which 1,848 were excluded. Full-text assessment was
performed for 124 articles, and 116 were excluded for predefined eligibility criteria. Ultimately, eight primary
studies were included in the qualitative synthesis.
DIE, deep infiltrating endometriosis
Study Characteristics
The broadened evidence framework includes direct comparative studies and primary cohorts reporting
postoperative outcomes after surgery for DIE. The direct comparison by Rezende et al. included 122 women
with bowel DIE treated surgically or with hormone-based therapy
[15]
. The DIAMOND trial was a randomized
comparison intended to recruit 320 participants but randomized only 18
[10]
.
Complementary surgical studies include the multicenter prospective cohort reported by Byrne et al., the
prospective cohort of 134 women undergoing bowel surgery reported by Hudelist et al., the retrospective
cohort of 195 women reported by Bourdel et al., and the historical series of 193 women undergoing
rectosigmoid resection reported by Raos et al.
[16-19]
. Additional cohorts evaluated gastrointestinal
function and long-term pain, quality of life, fertility, and recurrence after surgery
[20,21]
.
These studies contribute useful information across the review outcomes, but they do not all answer the same
treatment question. In particular, a postoperative improvement in a surgical cohort cannot by itself
demonstrate that surgery is superior to medical treatment. The characteristics and principal findings of the
included studies are summarized in Table
1
.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
4
of
13
Study
Design and population
Treatment or
exposure
Main outcomes and findings
Evidence
category
Cooper et
al.
[10]
Multicenter randomized trial; 18
participants randomized
Planned surgery
versus optimized
medical management
Recruitment and follow-up insufficient to
estimate comparative effectiveness
Direct
comparison,
inconclusive
Rezende
et al.
[15]
Retrospective cohort; 122 women with
bowel DIE
Surgery (n = 61)
versus hormone-
based treatment (n =
61)
Both groups improved; surgery was
associated with greater and more sustained
improvement in selected pain symptoms
Direct
comparison
Byrne et
al.
[16]
Multicenter prospective cohort; 4,721
planned excisions among 5,162 women
with rectovaginal endometriosis
Laparoscopic
excision
Pain and quality of life improved; overall
complication incidence 6.8%
Surgical
outcomes
Hudelist et
al.
[17]
Prospective cohort; 134 women with
colorectal DIE
Disk resection versus
segmental resection
Both procedures improved pain and quality
of life; pregnancy outcomes reported; serious
complications in 5.9%
Surgical
technique
comparison
Bourdel et
al.
[18]
Retrospective cohort; 195 women with
large rectovaginal nodules
Rectal shaving
versus colorectal
resection
Pain improved in both groups; pregnancy
rates 73% and 69%; major complications
more frequent after resection
Surgical
technique
comparison
Raos et
al.
[19]
Historical case series; 193 women with
rectosigmoid DIE and pregnancy
intention
Rectosigmoid
resection
Pregnancy rate 60.6%; live-birth rate 53.9%
Fertility
outcomes
after
surgery
Dior et al.
[20]
Prospective cohort; 149 patients with
deep endometriosis
Surgery
Bowel function and bowel-related quality of
life improved
Surgical
outcomes
Meuleman
et al.
[21]
Retrospective cohort; 56 patients with
deep colorectal endometriosis
Multidisciplinary
laparoscopic excision
Pain, quality of life, and sexual activity
improved; recurrence and pregnancy
outcomes reported
Surgical
outcomes
TABLE
1: Primary studies contributing evidence on DIE outcomes.
This table summarizes the study designs, populations, interventions or exposures, principal clinical outcomes, and evidence categories of the eight
included studies investigating surgical and medical management of DIE. The studies evaluated pain relief, quality of life, bowel function, fertility outcomes,
pregnancy rates, recurrence, and treatment-related complications. Evidence included direct comparisons between surgery and medical treatment,
comparisons of surgical techniques, and observational studies reporting outcomes following surgical intervention. The heterogeneity in study design,
population characteristics, and outcome measures was considered when interpreting the findings.
DIE, deep infiltrating endometriosis
Direct Comparison of Surgery and Medical Treatment
Rezende et al. conducted a retrospective cohort study of 122 women with bowel DIE, with 61 women
receiving surgery and 61 receiving hormone-based treatment
[15]
. Both groups experienced improvement in
pain symptoms. Surgery was associated with greater and more sustained improvement in chronic pelvic
pain, dyschezia, and deep dyspareunia. However, surgery was undertaken because of poor pain control, and
some women received hormonal suppression after surgery. The results therefore reflect selected treatment
pathways and cannot be interpreted as an unbiased causal comparison.
The DIAMOND trial was designed to compare early planned laparoscopic surgery, with or without adjuvant
medical treatment, against optimized medical management alone
[10]
. The primary outcome was the pain
domain of the Endometriosis Health Profile-30 at 18 months, with a planned economic evaluation. Although
377 patients were screened and 103 were eligible, only 18 participants were randomized against a planned
sample of 320. No participant reached the primary 18-month outcome. The trial could not establish
comparative clinical effectiveness or cost-effectiveness. Its failure to demonstrate a difference should not be
interpreted as evidence that the two treatments are equivalent. The outcome-specific evidence and its
principal limitations are summarized in Table
2
.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
5
of
13
Outcome
Evidence identified
Interpretation
Principal limitation
Pain relief
Rezende et al.
[15]
and
surgical cohorts
Both medical and surgical treatment were associated
with improvement in pain; surgical cohorts reported
postoperative improvement
Confounding by indication and
limited direct comparative
evidence
Quality of life
Byrne et al.
[16]
, Dior et al.
[20]
, Meuleman et al.
[21]
Improvement following surgery was reported across
disease-specific and general quality-of-life measures
Limited direct comparison with
medical treatment
Fertility
Hudelist et al.
[17]
, Bourdel et
al.
[18]
, Raos et al.
[19]
Pregnancy and live birth were reported following surgery
in selected patients
No reliable evidence of
superiority over nonsurgical
management
Recurrence
Bourdel et al.
[18]
, Meuleman
et al.
[21]
Recurrence and repeat intervention were reported, with
estimates varying by definition and follow-up
Heterogeneous definitions and
limited comparative evidence
Surgical
complications
Byrne et al.
[16]
, Hudelist et
al.
[17]
, Bourdel et al.
[18]
,
Raos et al.
[19]
Complication risk varied according to procedure and
disease extent
Differences in case mix and
complication definitions
Medical
adverse
effects
External hormonal-treatment
literature
Hormonal treatment may cause treatment-related
adverse effects that influence tolerability
Not adequately evaluated in
the included comparative
studies
Cost-
effectiveness
DIAMOND trial
[10]
Comparative cost-effectiveness remained unresolved
Insufficient recruitment and
absence of completed primary
outcome data
TABLE
2: Summary of evidence for clinical outcomes following surgical and medical treatment of
DIE.
This table summarizes the evidence relating to pain relief, quality of life, fertility, recurrence, surgical complications, medical adverse effects, and cost-
effectiveness in DIE. Evidence from the eight included primary studies is distinguished from external contextual literature. Direct comparisons between
surgery and medical treatment are presented separately from observational surgical outcomes and surgical technique comparisons. The heterogeneity of
study designs, populations, and outcome definitions limits definitive comparisons between treatment approaches.
DIE, deep infiltrating endometriosis
Pain Outcomes
Direct comparative evidence regarding pain relief was primarily provided by Rezende et al.
[15]
. Both the
surgical and hormone-based treatment groups experienced improvement in pain symptoms. However,
surgery was associated with greater and more sustained improvement in selected symptoms, including
chronic pelvic pain, dyschezia, and deep dyspareunia. As treatment allocation was nonrandomized, these
findings may have been influenced by differences in baseline symptoms, treatment selection, and
postoperative hormonal suppression.
The DIAMOND trial was designed to compare early planned laparoscopic surgery, with or without adjuvant
medical treatment, against optimized medical management alone
[10]
. Although 377 patients were screened
and 103 were eligible, only 18 participants were randomized. No participant reached the primary 18-month
outcome. Consequently, the trial could not establish comparative clinical effectiveness, and its findings
cannot be interpreted as evidence of equivalence between surgery and medical treatment.
Postoperative improvements in pain were also reported in several surgical cohorts. In the multicenter
prospective cohort reported by Byrne et al., women undergoing planned laparoscopic excision experienced
significant reductions in premenstrual, menstrual, and noncyclical pelvic pain, deep dyspareunia, dyschezia,
low back pain, and bladder pain at six months
[16]
. Improvements were generally maintained at two years,
although improvement in voiding difficulty was an exception.
Bourdel et al. reported significant reductions in pelvic pain and dysmenorrhea following both rectal shaving
and colorectal resection
[18]
. Mean pelvic pain scores decreased from 5.5 to 2.3 in the rectal-shaving group
and from 7.3 to 2.0 in the colorectal-resection group. Meuleman et al. also reported improvements in
gynecological pain following multidisciplinary laparoscopic excision
[21]
. These findings indicate
postoperative symptom improvement but do not establish the superiority of surgery over medical treatment.
Bowel and Urinary Function
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
6
of
13
Bowel and urinary outcomes were reported mainly in observational surgical cohorts. In the Byrne et al.
multicenter cohort, improvements were observed in bowel-related symptoms, including dyschezia,
following laparoscopic excision
[16]
. Bladder pain also decreased during follow-up, although improvement
in voiding difficulty was not maintained to the same extent as other reported symptoms.
Dior et al. prospectively followed 149 patients after surgery for deep endometriosis
[20]
. Mean bowel pattern
scores improved from 4.8 before surgery to 4.2 at 12 months. The impact of bowel symptoms on quality of
life improved from 5.5 before surgery to 4.4 at six months. Patients with direct lower gastrointestinal
involvement and poorer baseline bowel function tended to experience greater improvement.
These findings suggest that surgery may improve bowel symptoms and bowel-related quality of life in
selected patients. However, the absence of nonsurgical control groups in these cohorts limits conclusions
about the comparative effectiveness of surgery and medical treatment.
Quality-of-Life Outcomes
Improvement in quality of life following surgery was reported in the Byrne, Dior, and Meuleman cohorts
[16,20,21]
. In the Byrne et al. study, median global quality-of-life scores increased from 55/100 before
surgery to 80/100 at six months, with improvements maintained through two years
[16]
. Analgesic use also
decreased, including opioid use from 28.1% before surgery to 16.1% at six months.
Dior et al. reported improvement in bowel-related quality of life following surgery, with the mean bowel-
impact score decreasing from 5.5 before surgery to 4.4 at six months
[20]
. Meuleman et al. also reported
significant improvements in quality of life and sexual activity after multidisciplinary laparoscopic excision
[21]
.
Although these studies consistently reported postoperative improvement, differences in assessment
instruments, follow-up periods, patient characteristics, and surgical procedures prevented direct
comparison of the magnitude of benefit across studies. Most of these findings were derived from
uncontrolled surgical cohorts and therefore do not demonstrate that surgery provides greater quality-of-life
improvement than medical treatment.
Fertility and Pregnancy Outcomes
Fertility evidence primarily comes from surgical cohorts rather than direct comparisons with medical
treatment. In the prospective cohort of 134 women with colorectal DIE reported by Hudelist et al., 61
women had a history of infertility. Among these, 26 conceived spontaneously and 13 conceived through in
vitro fertilization, corresponding to an overall pregnancy rate of 63.4% in that subgroup
[17]
. The study
compared disk resection with segmental resection, not surgery with medical treatment.
Bourdel et al. reported pregnancy rates of 73% after rectal shaving and 69% after colorectal resection among
women seeking pregnancy
[18]
. These rates were not significantly different between the surgical techniques.
In the historical cohort of 193 women undergoing rectosigmoid resection, Raos et al. reported postoperative
pregnancy and live-birth rates of 60.6% and 53.9%, respectively
[19]
. Pregnancy occurred spontaneously in
20.2% of the full cohort, while the remainder of pregnancies involved intrauterine insemination or assisted
reproductive technology.
These observations demonstrate that pregnancy and live birth are possible after surgery for bowel DIE. They
do not establish that surgery improves fertility compared with expectant management or medical treatment,
because the studies lacked an appropriate direct comparison. Fertility outcomes depend on age, ovarian
reserve, tubal function, other infertility factors, reproductive intention, and use of assisted reproductive
technology.
Recurrence and Repeat Intervention
Recurrence outcomes varied by study and definition. Meuleman et al. reported cumulative recurrence of 2%
at one year and 7% at four years after multidisciplinary laparoscopic excision
[21]
. In the Bourdel et al.
cohort, 13 women in the rectal-shaving group underwent repeat surgery for suspected recurrence, compared
with none in the colorectal-resection group; the difference was not statistically significant
[18]
. The authors
noted that the repeat operations did not all confirm recurrent endometriosis.
These results should not be interpreted as establishing a universal recurrence rate or as demonstrating that
one surgical technique consistently prevents recurrence better than another. Differences in lesion extent,
operative approach, postoperative hormonal treatment, follow-up duration, and the definition of recurrence
limit comparisons. They also do not establish whether surgery prevents recurrence more effectively than
medical treatment. The study characteristics and reported clinical outcomes are presented in Table
3
.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
7
of
13
Study
Sample and design
Outcome
assessed
Reported findings
Interpretation
Rezende
et al.
[15]
122 women with bowel
DIE; retrospective
comparative cohort
Chronic pelvic pain,
dysmenorrhea,
deep dyspareunia,
dyschezia, and
dysuria
Both surgery and hormone-based
treatment improved pain; surgery was
associated with greater and more
sustained improvement in selected
symptoms
Direct comparative evidence,
limited by nonrandomized
treatment allocation and
possible confounding
Byrne et
al.
[16]
5,162 women with
rectovaginal endometriosis
across 51 specialist
centers; multicenter
prospective cohort
Pelvic pain, bowel
and urinary
symptoms,
analgesic use, and
quality of life
Pain and quality of life improved
following planned laparoscopic
excision, with benefits generally
maintained during follow-up
Large multicenter evidence of
postoperative improvement, but
no medical-treatment control
group
Hudelist et
al.
[17]
134 women with colorectal
DIE; prospective cohort
Pain, fertility, and
complications
Pain outcomes and pregnancies were
assessed after disk or segmental bowel
resection
Useful for surgical outcomes
and technique comparisons,
not direct comparison with
hormonal treatment
Bourdel et
al.
[18]
195 women with large
rectovaginal nodules;
retrospective cohort
Pain, pregnancy,
recurrence, and
complications
Pain improved after rectal shaving and
colorectal resection; pregnancy was
reported in women seeking conception
Technique-specific
observational evidence subject
to selection bias
Raos et
al.
[19]
193 women undergoing
rectosigmoid resection;
historical cohort
Pregnancy and live
birth
Postoperative pregnancies and live
births were reported in a cohort with
fertility intentions
Demonstrates reproductive
outcomes after surgery but
does not establish a fertility
benefit over nonsurgical
management
Dior et al.
[20]
149 patients; prospective
cohort
Bowel function and
bowel-related
quality of life
Bowel symptoms and their impact on
quality of life improved following surgery
Supports postoperative
functional improvement;
comparative effectiveness
remains uncertain
Meuleman
et al.
[21]
56 patients; retrospective
cohort
Pain, quality of life,
sexual activity,
recurrence, and
pregnancy
Improvements in pain and quality of life
were reported after multidisciplinary
laparoscopic excision
Small observational cohort with
limited ability to establish long-
term comparative effects
TABLE
3: Study characteristics and reported pain, quality-of-life, and fertility outcomes following
treatment of DIE.
This table summarizes the clinical outcomes reported in seven studies evaluating surgical management of DIE. The outcomes include pelvic pain,
dysmenorrhea, dyspareunia, bowel and urinary symptoms, quality of life, fertility, pregnancy, live birth, recurrence, and postoperative complications.
Cooper et al.
[10]
was not included in this table because the DIAMOND trial did not produce completed primary outcome data. The predominantly
observational nature of the included studies limits conclusions regarding the comparative effectiveness of surgery and medical treatment.
DIE, deep infiltrating endometriosis
Treatment-Related Complications
In the Byrne et al. cohort, the overall incidence of complications after planned laparoscopic excision was
6.8%
[16]
. Gastrointestinal complications, including enterotomy, anastomotic leak, or fistula, occurred in
1.1% of procedures, while urinary tract complications, including ureteric or bladder injury or leakage,
occurred in 1.0%.
In the Bourdel et al. cohort, major complications occurred in 4% of women undergoing rectal shaving and
26% of those undergoing colorectal resection, a statistically significant difference
[18]
. The comparison was
observational, and the resection group was small; the findings may therefore reflect differences in disease
severity and surgical indication as well as procedure-related risk.
Hudelist et al. reported serious complications classified as Clavien-Dindo grades III-IV in 5.9% of the 134
women undergoing disk or segmental bowel resection, with no statistically significant difference between
the two surgical groups
[17]
. Raos et al. reported grade III complications in 16.6% of the 193 women
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
8
of
13
undergoing rectosigmoid resection
[19]
. These estimates should not be compared directly because patient
populations, definitions, procedures, and reporting methods differed.
Medical treatment also has potential harms, including irregular bleeding, mood-related symptoms, sexual
adverse effects, and drug-specific hypoestrogenic or bone-related effects. The available direct comparative
evidence does not provide a sufficiently standardized basis to determine the overall safety superiority of
surgery or medical treatment.
Discussion
Principal Findings
The expanded evidence base provides a broader view of outcomes following surgery for DIE than direct
comparative studies alone. Observational cohorts consistently report improvement in pain and quality of
life after surgical excision, while fertility studies document pregnancies and live births after surgery.
However, direct comparative evidence remains insufficient to establish whether surgery is superior to
medical treatment across all clinical outcomes.
The distinction between direct and indirect evidence is fundamental. A before-and-after surgical cohort can
show that symptoms improved following an operation, but it cannot determine how much improvement
would have occurred with medical therapy, expectant management, or changes in concomitant treatment.
Similarly, comparisons between rectal shaving and segmental resection address the choice of surgical
technique rather than the decision between surgery and medical treatment.
Pain and Quality of Life
The direct comparative cohort by Rezende et al. suggests that surgery may provide more sustained relief of
selected pain symptoms in women with bowel DIE
[15]
. The large prospective cohort by Byrne et al. provides
complementary evidence that pain, bowel and urinary symptoms, analgesic use, and quality of life can
improve after laparoscopic excision
[16]
.
Nevertheless, pain is multidimensional, and symptom improvement does not necessarily indicate complete
disease eradication. Persistent pain may be associated with residual lesions, pelvic floor dysfunction,
neuropathic mechanisms, or central sensitization. Treatment decisions should therefore consider the
specific symptom pattern, anatomical findings, previous treatment response, and patient priorities
[22,23]
.
The observed improvement in quality of life after surgery is clinically important, but the absence of robust
direct comparisons limits claims of superiority over medical therapy. Future studies should use validated
instruments, such as the Endometriosis Health Profile-30
[24]
, and report between-group differences with
CIs at prespecified follow-up times.
Fertility Considerations
Surgical cohorts show that pregnancy is achievable after treatment of rectosigmoid DIE. However,
postoperative pregnancy rates cannot be interpreted as proof that surgery improves fertility compared with
medical management or expectant treatment. Fertility studies are particularly vulnerable to selection bias
because they include women who intend to conceive and may subsequently use assisted reproductive
technology.
Fertility-related decisions should account for age, ovarian reserve, tubal status, previous operations, lesion
location, and other infertility factors. Surgery involving bowel or urinary tract structures also carries risks
that must be balanced against anticipated benefits. Hormonal suppression may be useful for symptom
control in women not seeking immediate pregnancy, but it generally prevents conception attempts while
treatment continues
[7,9,25]
.
Recurrence and Repeat Treatment
Recurrence should be separated into recurrent symptoms, imaging-confirmed lesions, confirmed disease at
repeat surgery, and the need for additional treatment. These outcomes are not interchangeable. Some
women undergo repeat intervention for pain without histologically confirmed recurrence, while others may
have recurrent disease without undergoing another operation.
The available surgical cohorts show that recurrence and repeat intervention remain possible, but do not
provide a reliable direct comparison with medical treatment. Postoperative hormonal suppression may be
appropriate for selected women who are not seeking immediate pregnancy, although its effect must be
distinguished from the effect of surgery itself.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
9
of
13
Complications and Treatment Selection
Surgical risk varies substantially according to the organs involved, the extent of fibrosis, the need for bowel
or urinary tract reconstruction, patient comorbidities, and specialist expertise. The large multicenter cohort
demonstrates that surgery can be associated with improved symptoms and quality of life, but
gastrointestinal and urinary tract complications remain important considerations
[16]
.
The higher complication rate observed after colorectal resection than after rectal shaving in the Bourdel et
al. cohort should be interpreted cautiously because the choice of procedure is influenced by lesion extent
and depth
[18]
. More extensive disease may require more extensive surgery, and observational comparisons
cannot completely separate procedural effects from differences in the underlying disease.
Medical treatment avoids immediate operative risks but has its own adverse effects and may require
prolonged use or repeated treatment changes. The available evidence does not establish that either strategy
is uniformly safer. Shared decision-making should explain both the potential benefits and the risks of each
approach.
Strengths and Limitations
This systematic review has several strengths. It synthesizes evidence from eight primary studies addressing
clinically important outcomes of DIE, including pain, quality of life, bowel function, fertility, recurrence,
and treatment-related complications. The literature search covered five major electronic databases: PubMed,
Embase, Scopus, Web of Science Core Collection, and CENTRAL. Reference lists of relevant publications
were also examined to identify additional eligible studies. Two reviewers independently screened titles,
abstracts, and full-text articles, with disagreements resolved through discussion and consensus.
Furthermore, the review distinguishes direct comparisons between surgery and medical treatment from
observational surgical cohorts and studies comparing different surgical techniques. This distinction is
important because postoperative improvement in an uncontrolled surgical cohort does not establish the
superiority of surgery over medical treatment.
The included studies had several methodological limitations that affected the certainty of the findings.
These included nonrandomized treatment allocation, confounding by indication, limited direct comparisons
with medical management, and differences in disease severity, lesion location, and surgical techniques.
Women selected for surgery may have had more severe symptoms, extensive disease, or inadequate
responses to previous medical treatment, whereas those receiving medical treatment may have differed in
reproductive intentions, disease characteristics, or suitability for surgery. These differences may have
influenced the observed outcomes independently of the treatment received. Variations in outcome
definitions and follow-up duration further limited comparisons of recurrence, fertility, and complications.
In particular, pregnancy, clinical pregnancy, and live birth represent distinct reproductive outcomes, while
symptomatic recurrence and recurrence requiring repeat surgery are not interchangeable endpoints.
Insufficient recruitment in the available randomized controlled trial also restricted conclusions regarding
comparative effectiveness. The principal methodological limitations and their implications for
interpretation are summarized in Table
4
.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
10
of
13
Methodological
issue
How it affects the evidence
Implication for this review
Confounding by
indication
Women selected for surgery may have more severe
symptoms, extensive lesions, or inadequate response
to medical treatment
Differences between treatment groups may reflect baseline
differences as well as treatment effects
Nonrandomized
treatment
allocation
Treatment selection may be influenced by clinician
judgment, patient preferences, fertility plans, and
surgical suitability
Observational associations should not be interpreted as
causal effects
Absence of a
medical control
group
Surgical cohorts commonly compare symptoms before
and after surgery without a nonsurgical comparator
Postoperative improvement does not establish superiority
over medical treatment
Variation in lesion
location
Bowel, bladder, ureteric, and rectovaginal disease have
different clinical consequences and surgical
requirements
Outcomes should be stratified by lesion location where
data permit
Differences in
surgical technique
Rectal shaving, discoid excision, and segmental
resection are not interchangeable procedures
Comparisons between techniques should remain separate
from surgery-versus-medical-treatment comparisons
Concomitant
hormonal
suppression
Postoperative medication may contribute to symptom
control or recurrence prevention
Studies should distinguish surgery alone from surgery
combined with postoperative hormonal treatment
Inconsistent
outcome
definitions
Symptom recurrence, radiological recurrence, repeat
surgery, and treatment resumption measure different
outcomes
Recurrence results should not be combined without
compatible definitions
Heterogeneous
fertility outcomes
Spontaneous pregnancy, assisted reproduction, clinical
pregnancy, and live birth are distinct endpoints
Fertility outcomes should be reported separately and
interpreted in light of reproductive intention
Variable follow-up
duration
Short follow-up may miss recurrence or late
complications
Long-term outcomes require adequate and clearly reported
follow-up
Inadequately
powered
randomized
evidence
The DIAMOND trial did not recruit enough participants
to establish comparative effectiveness
The lack of a definitive randomized result is uncertainty, not
proof of equivalent treatment effects
Incomplete search
verification
Unverified database searches may miss eligible studies
Final study counts, risk-of-bias assessments, and the
PRISMA flow diagram must await completion of the search
and screening process
TABLE
4: Methodological limitations and their implications for interpreting evidence on surgical
versus medical treatment of DIE.
This table summarizes the principal methodological limitations considered when interpreting the evidence on surgical and medical management of DIE.
The limitations relate to treatment selection, study design, disease characteristics, surgical techniques, concomitant treatment, outcome definitions, fertility
reporting, follow-up duration, and completeness of outcome data. These issues were considered descriptively during the narrative synthesis. Formal
study-level risk-of-bias assessments using the Cochrane RoB 2 tool and ROBINS-I were not performed.
DIE, deep infiltrating endometriosis; RoB 2, Risk of Bias 2; ROBINS-I, Risk Of Bias In Non-randomized Studies of Interventions
The systematic review itself also has limitations. Although the study-selection process followed the PRISMA
2020 framework
[11]
, formal study-level risk-of-bias assessments using the Cochrane RoB 2 tool
[13]
and
ROBINS-I
[14]
were not performed. No formal GRADE assessment of certainty of evidence was undertaken.
Consequently, methodological limitations were considered descriptively rather than through formal risk-of-
bias classifications. In addition, the included studies differed in design, populations, disease characteristics,
interventions, surgical techniques, and outcome measurements. This heterogeneity prevented meaningful
quantitative pooling, and a narrative synthesis was therefore undertaken without calculating pooled
treatment-effect estimates.
Overall, these limitations restrict the certainty of conclusions regarding the comparative effectiveness of
surgery and medical treatment for DIE. The findings should be interpreted as a synthesis of the available
comparative and observational evidence rather than definitive evidence that either treatment strategy is
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
11
of
13
universally superior. Treatment decisions should be individualized according to symptom severity,
anatomical disease extent, reproductive plans, previous treatment response, and the potential benefits and
risks of each approach.
Future Research Directions
Future research should prioritize adequately powered multicenter randomized controlled trials comparing
surgical excision with optimized medical treatment in women with DIE. Such studies should use clearly
defined eligibility criteria, standardized treatment protocols, and validated outcome measures, including
pain scores and the Endometriosis Health Profile-30. Prespecified follow-up intervals should permit
assessment of both short-term symptom improvement and long-term recurrence.
Studies should also report fertility outcomes separately, distinguishing spontaneous conception, assisted
reproductive technology, clinical pregnancy, and live birth. Surgical complications should be classified using
standardized systems, with separate reporting of bowel, urinary, vascular, and neurological complications.
Longer follow-up is required to assess recurrence and repeat intervention reliably.
Future comparative studies should address baseline disease severity, lesion location, previous treatment,
fertility intention, and concomitant postoperative hormonal therapy. Reporting adjusted effect estimates
with 95% CIs would improve interpretation of treatment differences and reduce the risk of over-interpreting
uncontrolled postoperative improvements.
Conclusions
Surgery for DIE is associated with improvements in pain, bowel function, and quality of life, with
pregnancies and live births reported in selected women. However, treatment-related complications remain
important, and a fertility benefit over medical or expectant management has not been established. Direct
comparative evidence is limited, and the available randomized trial was inconclusive because of inadequate
recruitment. Therefore, surgery cannot be considered universally superior to medical treatment.
Management should be individualized according to symptoms, anatomical disease extent, reproductive
plans, previous treatment response, and the risks associated with each approach.
Additional Information
Author Contributions
All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the
work.
Concept and design:
Mosammat Shahana Jesmin, Saria Tasnim, Marjia Begum, Alauddin ., Farah Parisha
Bhuiyan
Acquisition, analysis, or interpretation of data:
Mosammat Shahana Jesmin
Drafting of the manuscript:
Mosammat Shahana Jesmin, Saria Tasnim, Alauddin .
Critical review of the manuscript for important intellectual content:
Mosammat Shahana Jesmin,
Marjia Begum, Farah Parisha Bhuiyan
Supervision:
Mosammat Shahana Jesmin, Farah Parisha Bhuiyan
Disclosures
AI use statement:
The authors used ChatGPT (GPT-6; OpenAI, San Francisco, CA, USA) as follows:
language polishing, structure or formatting in Introduction and Discussion. The AI-generated content was
manually reviewed by cross-checking factual statements, clinical findings, and statistical data against the
original studies and available source publications. Sample sizes, study characteristics, outcome measures,
and reported statistical values were checked for consistency. References were verified using original journal
articles, DOI links, and PubMed records, wherever available. Inaccuracies, unsupported claims, and
inconsistencies were corrected, and the final manuscript was reviewed to ensure scientific accuracy and
appropriate interpretation. The authors confirm that they have reviewed and verified all AI-assisted content
and take full responsibility for the work.
Conflicts of interest:
In compliance with the ICMJE uniform
disclosure form, all authors declare the following:
Payment/services info:
All authors have declared that no
financial support was received from any organization for the submitted work.
Financial relationships:
All
authors have declared that they have no financial relationships at present or within the previous three years
with any organizations that might have an interest in the submitted work.
Other relationships:
All authors
have declared that there are no other relationships or activities that could appear to have influenced the
submitted work.
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
12
of
13
References
1
.
Martire FG, Giorgi M, D'Abate C, et al.:
Deep infiltrating endometriosis in adolescence: early diagnosis and
possible prevention of disease progression
. J Clin Med. 2024, 13:550.
10.3390/jcm13020550
2
.
Zondervan KT, Becker CM, Missmer SA:
Endometriosis
. N Engl J Med. 2020, 382:1244-56.
10.1056/NEJMra1810764
3
.
Rajesh S, Mehmeti A, Smith-Walker T, Kendall B:
Diagnosis and management of endometriosis: summary
of updated NICE guidance
. BMJ. 2025, 388:q2782.
10.1136/bmj.q2782
4
.
Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ:
Suggestive evidence that pelvic
endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic
pain
. Fertil Steril. 1991, 55:759-65.
10.1016/s0015-0282(16)54244-7
5
.
Donnez O, Roman H:
Choosing the right surgical technique for deep endometriosis: shaving, disc excision,
or bowel resection?
. Fertil Steril. 2017, 108:931-42.
10.1016/j.fertnstert.2017.09.006
6
.
Ugwumadu L, Chakrabarti R, Williams-Brown E, et al.:
The role of the multidisciplinary team in the
management of deep infiltrating endometriosis
. Gynecol Surg. 2017, 14:15.
10.1186/s10397-017-1018-0
7
.
Endometriosis: diagnosis and management
. (2017). Accessed: October 30, 2026:
https://www.nice.org.uk/guidance/ng73
.
8
.
D'Alterio MN, D'Ancona G, Raslan M, Tinelli R, Daniilidis A, Angioni S:
Management challenges of deep
infiltrating endometriosis
. Int J Fertil Steril. 2021, 15:88-94.
10.22074/IJFS.2020.134689
9
.
Becker CM, Bokor A, Heikinheimo O, et al.:
ESHRE guideline: endometriosis
. Hum Reprod Open. 2022,
2022:hoac009.
10.1093/hropen/hoac009
10
.
Cooper K, Constable L, Vadiveloo T, et al.:
Clinical and cost-effectiveness of medical management versus
surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
. Health Technol Assess. 2026,
30:437-64.
10.3310/GJKC5715
11
.
Page MJ, McKenzie JE, Bossuyt PM, et al.:
The PRISMA 2020 statement: an updated guideline for reporting
systematic reviews
. BMJ. 2021, 372:n71.
10.1136/bmj.n71
12
.
Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, Koffel JB:
PRISMA-S: an extension
to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews
. Syst Rev. 2021, 10:39.
10.1186/s13643-020-01542-z
13
.
Sterne JA, Savović J, Page MJ, et al.:
RoB 2: a revised tool for assessing risk of bias in randomised trials
. BMJ.
2019, 366:l4898.
10.1136/bmj.l4898
14
.
Sterne JA, Hernán MA, Reeves BC, et al.:
ROBINS-I: a tool for assessing risk of bias in non-randomised
studies of interventions
. BMJ. 2016, 355:i4919.
10.1136/bmj.i4919
15
.
Rezende GP, Venturini MC, Kawagoe LN, Yela Gomes DA, Benetti-Pinto CL:
Surgery vs. hormone-based
treatment for pain control in deep infiltrating endometriosis: a retrospective cohort study
. Curr Med Res
Opin. 2022, 38:641-7.
10.1080/03007995.2022.2031940
16
.
Byrne D, Curnow T, Smith P, Cutner A, Saridogan E, Clark TJ:
Laparoscopic excision of deep rectovaginal
endometriosis in BSGE endometriosis centres: a multicentre prospective cohort study
. BMJ Open. 2018,
8:e018924.
10.1136/bmjopen-2017-018924
17
.
Hudelist G, Aas-Eng MK, Birsan T, et al.:
Pain and fertility outcomes of nerve-sparing, full-thickness disk or
segmental bowel resection for deep infiltrating endometriosis—a prospective cohort study
. Acta Obstet
Gynecol Scand. 2018, 97:1438-46.
10.1111/aogs.13436
18
.
Bourdel N, Comptour A, Bouchet P, et al.:
Long-term evaluation of painful symptoms and fertility after
surgery for large rectovaginal endometriosis nodule: a retrospective study
. Acta Obstet Gynecol Scand. 2018,
97:158-67.
10.1111/aogs.13260
19
.
Raos M, Mathiasen M, Seyer-Hansen M:
Impact of surgery on fertility among patients with deep infiltrating
endometriosis
. Eur J Obstet Gynecol Reprod Biol. 2023, 280:174-8.
10.1016/j.ejogrb.2022.12.004
20
.
Dior UP, Reddington C, Cheng C, Levin G, McInerney C, Moss A, Healey M:
Lower gastrointestinal function
after surgery for deep endometriosis: a prospective cohort study
. Int J Gynaecol Obstet. 2023, 160:280-8.
10.1002/ijgo.14350
21
.
Meuleman C, D'Hoore A, Van Cleynenbreugel B, Beks N, D'Hooghe T:
Outcome after multidisciplinary CO2
laser laparoscopic excision of deep infiltrating colorectal endometriosis
. Reprod Biomed Online. 2009,
18:282-9.
10.1016/S1472-6483(10)60267-2
22
.
Green IC, Burnett T, Famuyide A:
Persistent pelvic pain in patients with endometriosis
. Clin Obstet Gynecol.
2022, 65:775-85.
10.1097/GRF.0000000000000712
23
.
McNamara HC, Frawley HC, Donoghue JF, et al.:
Peripheral, central, and cross sensitization in
endometriosis-associated pain and comorbid pain syndromes
. Front Reprod Health. 2021, 3:729642.
10.3389/frph.2021.729642
24
.
Jones G, Kennedy S, Barnard A, Wong J, Jenkinson C:
Development of an endometriosis quality-of-life
instrument: the Endometriosis Health Profile-30
. Obstet Gynecol. 2001, 98:258-64.
10.1016/s0029-
7844(01)01433-8
25
.
Harada T, Taniguchi F, Kitajima M, et al.:
Clinical practice guidelines for endometriosis in Japan (The 3rd
edition)
. J Obstet Gynaecol Res. 2022, 48:2993-3044.
10.1111/jog.15416
2026 Jesmin et al. Cureus 18(11): e119919. DOI 10.7759/cureus.119919
13
of
13
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.